drugset / Trial / NCT03167255
Extension Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)
Phase 2
Completed
16 enrolled
NS Pharma, Inc.
Cooperative International Neuromuscular Research Group · collabNippon Shinyaku Co., Ltd. · collabTherapeutic Research in Neuromuscular Disorders Solutions · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, extension study of NS-065/NCNP-01 administered intravenously once weekly for an additional 192 weeks to boys with DMD who complete Study NS-065/NCNP-01-201.
Timeline
- Start
- 2017-07-06
- Primary completion
- 2021-10-20
- Completion
- 2021-11-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Viltolarsen | Unknown | 40 mg/kg | Intravenous |
| Subject | Viltolarsen | Unknown | 80 mg/kg | Intravenous |